Alto Neuroscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANRO research report →
Range $37 – $60
Price Chart
About the company
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder.
- CEO
- Amit Etkin
- IPO
- 2024
- Employees
- 68
- HQ
- Mountain View, CA, US
Get TickerSpark's AI analysis on ANRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $999.16M
- P/E
- -9.96
- PEG
- 1.05
- P/S
- 0.00
- P/B
- 3.91
- EV/EBITDA
- -7.61
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.82%
- ROIC
- 10.23%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-661,000-31.7%
- Op Income
- $-66,364,000
- Net Income
- $-63,238,000-2.9%
- EPS
- $-2.19+12.4%
- OCF Growth
- -9.2%
- FCF Growth
- -4.6%
- Beta
- 1.16
- RSI (14)
- 51
No earnings-call transcripts are available for ANRO yet.
- Free Float
- 90.6%
- Shares Outstanding
- 40.11M
- Float Shares
- 36.34M
of shares held by institutions
120 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Alpha Wave Global, LP | 3.71M | 0 |
| Blackrock, Inc. | 2.73M | ▲ 605.10K |
| Commodore Capital LP | 2.72M | 0 |
| Vanguard Capital Management LLC | 1.69M | ▲ 301.28K |
| Spruce Street Capital LP | 1.68M | ▲ 323.51K |
| Perceptive Advisors LLC | 1.61M | ▼ 400.00K |
| Adage Capital Partners Gp, L.L.C. | 1.60M | ▲ 1.22M |
| Vanguard Group Inc | 1.37M | ▲ 260.44K |
| Vivo Capital, LLC | 1.36M | ▲ 151.06K |
| Franklin Templeton Inc | 993.49K | ▼ 19.82K |
| State Street Corp | 946.04K | ▲ 260.10K |
| Armistice Capital, LLC | 864.00K | ▼ 48.00K |
Held by 172 ETFs
Biggest fund positions in ANRO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Hanley Jr. Michael Conick | other | 17,729 |
| Nov 17, 26 | Hanley Jr. Michael Conick | other | 2,104 |
| Nov 18, 26 | Hanley Jr. Michael Conick | other | 2,896 |
| Nov 16, 26 | Hanley Jr. Michael Conick | other | 44,271 |
| Nov 16, 26 | Hanley Jr. Michael Conick | other | 8,000 |
| Nov 16, 26 | Hanley Jr. Michael Conick | other | 44,271 |
| Nov 16, 26 | Hanley Jr. Michael Conick | other | 17,729 |
| Nov 16, 26 | Hanley Jr. Michael Conick | sell | 56,410 |
| Nov 18, 26 | Hanley Jr. Michael Conick | other | 2,896 |
| Nov 16, 26 | Hanley Jr. Michael Conick | sell | 10,895 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANRO coverage
Recent articles, reports, and earnings notes.
No research on ANRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANRO report →